Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Cancer Research and Treatment. 2018;50(1):95-102 
PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Annals of Oncology. 2019;30:v510
PD-L1 expression in non-small cell lung cancer according to specimen type; a retrospective study of over 2,000 cases
Lung Cancer. 2020;139:S57
P2.04-94 PD-L1 Expression in Uncommon EGFR-Mutant Non-Small Cell Lung Cancer and Its Response to Immunotherapy
Journal of Thoracic Oncology. 2019;14(10):S747
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
Lung Cancer. 2020;142:98-105
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion
Lung Cancer. 2019;127:59-65
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy
Diagnostics. 2020;10(12):1006
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non–Small-Cell Lung Cancer and High PD-L1 Expression
Clinical Lung Cancer. 2021;
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
OncoTargets and Therapy. 2021;Volume 14:2301-2309
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer
Japanese Journal of Clinical Oncology. 2020;50(5):617-622